[go: up one dir, main page]

MX2016008201A - Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. - Google Patents

Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.

Info

Publication number
MX2016008201A
MX2016008201A MX2016008201A MX2016008201A MX2016008201A MX 2016008201 A MX2016008201 A MX 2016008201A MX 2016008201 A MX2016008201 A MX 2016008201A MX 2016008201 A MX2016008201 A MX 2016008201A MX 2016008201 A MX2016008201 A MX 2016008201A
Authority
MX
Mexico
Prior art keywords
cancer
erk
combinations
subject
effects
Prior art date
Application number
MX2016008201A
Other languages
English (en)
Other versions
MX384721B (es
Inventor
Saha Saurabh
Decrescenzo Gary
WELSCH Dean
James ROIX Jeffrey
Original Assignee
Biomed Valley Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries Inc filed Critical Biomed Valley Discoveries Inc
Publication of MX2016008201A publication Critical patent/MX2016008201A/es
Publication of MX384721B publication Critical patent/MX384721B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona, inter alia, métodos de tratamiento o mejoramiento de los efectos de un cáncer en un sujeto. Los métodos incluyen administrar al sujeto una cantidad efectiva de (i) un primer agente anticáncer, el cual es BVD-523 o una sal farmacéuticamente aceptable del mismo y (ii) un segundo agente anticáncer, el cual es un inhibidor de RF del tipo 1 (como el dabrafenib) u otro inhibidor de RAF (como regorafenib) o una sal farmacéuticamente aceptable de los mismos, para tratar o mejorar los efectos del cáncer. También se proporcionan composiciones y kits farmacéuticos para tratar o mejorar los efectos de un cáncer en un sujeto.
MX2016008201A 2013-12-20 2014-12-19 Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf. MX384721B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361919347P 2013-12-20 2013-12-20
PCT/US2014/071715 WO2015095819A2 (en) 2013-12-20 2014-12-19 Cancer treatment using combinations of erk and raf inhibitors

Publications (2)

Publication Number Publication Date
MX2016008201A true MX2016008201A (es) 2017-04-27
MX384721B MX384721B (es) 2025-03-14

Family

ID=53403899

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016008201A MX384721B (es) 2013-12-20 2014-12-19 Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
MX2021008610A MX394252B (es) 2013-12-20 2014-12-19 Tratamiento del cancer usando combinaciones de inhibidores de erk y raf

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008610A MX394252B (es) 2013-12-20 2014-12-19 Tratamiento del cancer usando combinaciones de inhibidores de erk y raf

Country Status (11)

Country Link
US (1) US10668055B2 (es)
EP (2) EP4043017A1 (es)
JP (1) JP6678585B2 (es)
CN (1) CN106211755B (es)
AU (1) AU2014368906B2 (es)
BR (1) BR112016014481B1 (es)
CA (3) CA3240745A1 (es)
ES (1) ES2909910T3 (es)
MX (2) MX384721B (es)
RU (1) RU2722784C2 (es)
WO (1) WO2015095819A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
SG10201600179RA (en) 2011-01-10 2016-02-26 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
HUE040126T2 (hu) 2012-11-01 2019-02-28 Infinity Pharmaceuticals Inc Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
US20180369195A1 (en) * 2015-11-30 2018-12-27 The Regents Of The University Of California Combination therapy for treatment of melanoma
CN109069646A (zh) * 2016-02-05 2018-12-21 埃沃尔科学有限责任公司 治疗癌症的组合
WO2017158621A1 (en) * 2016-03-14 2017-09-21 Sphaera Pharma Pvt. Ltd. Trigonelline based compounds
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
KR20240032157A (ko) 2017-05-02 2024-03-08 노파르티스 아게 병용 요법
WO2018213302A1 (en) * 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
WO2018226802A1 (en) 2017-06-06 2018-12-13 The Johns Hopkins University Induction of synthetic lethality with epigenetic therapy
KR20200037820A (ko) 2017-08-07 2020-04-09 에볼 사이언스 엘엘씨 암을 치료하기 위한 조합
WO2019073435A1 (en) * 2017-10-12 2019-04-18 Novartis Ag COMBINATIONS OF MDM2 INHIBITORS WITH ERK INHIBITORS TO TREAT CANCERS
CN111886025A (zh) * 2017-11-01 2020-11-03 新加坡国立大学 血清素能药物治疗病毒诱发的血小板减少症的用途
CN111417730A (zh) * 2017-11-20 2020-07-14 托雷莫治疗股份公司 诊断方法
WO2019103984A1 (en) * 2017-11-22 2019-05-31 Memorial Sloan Kettering Cancer Center Compositions including fatp1, fatp3, fatp4, fatp5, and/or fatp6 inhibitors and uses thereof
WO2019195959A1 (en) * 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CN113795490A (zh) 2019-05-13 2021-12-14 诺华股份有限公司 N-(3-(2-(2-羟基乙氧基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-2(三氟甲基)异烟酰胺的新结晶形式作为Raf抑制剂治疗癌症
CA3166636A1 (en) 2020-01-10 2021-07-15 Immuneering Corporation Mek inhibitors and therapeutic uses thereof
MX2023009642A (es) * 2021-02-19 2023-10-16 Day One Biopharmaceuticals Inc Combinacion de inhibidor de raf e inhibidor de mek.
CN113018269B (zh) * 2021-03-14 2022-06-03 华中科技大学同济医学院附属协和医院 复合颗粒物、其制备方法及其应用
TW202317121A (zh) * 2021-06-24 2023-05-01 美商艾瑞斯卡公司 Erk1/2及egfr抑制劑之組合療法
CN118510505A (zh) * 2021-10-28 2024-08-16 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合疗法
CN118647382A (zh) * 2021-11-02 2024-09-13 维瑞斯特姆股份有限公司 治疗异常细胞生长的方法
CN115400122B (zh) * 2022-04-29 2023-04-18 佛山病原微生物研究院 一种tak-632在制备用于抗腺病毒感染的药物中的用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
TW202517624A (zh) * 2023-07-03 2025-05-01 美商醫療免疫工程公司 Mek免疫腫瘤抑制劑醫藥組合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689610B1 (en) 1993-03-19 2002-07-03 Sequenom, Inc. Dna sequencing by mass spectrometry via exonuclease degradation
US6140053A (en) 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US7439016B1 (en) 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
GB0121490D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
GB0320059D0 (en) 2003-08-27 2003-10-01 Solexa Ltd A method of sequencing
ES2751761T3 (es) * 2004-05-14 2020-04-01 Vertex Pharma Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
CA2609387A1 (en) 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
DK2395004T3 (en) * 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
PE20090326A1 (es) * 2007-06-05 2009-04-04 Schering Corp Compuestos heterociclos como inhibidores de erk
ES2622062T3 (es) 2008-10-27 2017-07-05 Qiagen Gaithersburg, Inc. Ensayo y sistema de captura de híbrido de resultados rápidos
AR077975A1 (es) * 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
KR20120046018A (ko) 2010-10-04 2012-05-09 삼성테크윈 주식회사 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출
US20130217721A1 (en) 2010-11-19 2013-08-22 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
WO2012125848A2 (en) 2011-03-16 2012-09-20 Baylor College Of Medicine A method for comprehensive sequence analysis using deep sequencing technology
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors

Also Published As

Publication number Publication date
WO2015095819A3 (en) 2015-08-13
CA3168002C (en) 2024-10-22
RU2016129287A (ru) 2018-01-23
CA3240745A1 (en) 2015-06-25
RU2722784C2 (ru) 2020-06-03
EP3082800B1 (en) 2022-02-02
US20160310476A1 (en) 2016-10-27
BR112016014481B1 (pt) 2022-11-08
US10668055B2 (en) 2020-06-02
CA3168002A1 (en) 2015-06-25
CA2934669C (en) 2022-10-04
CA2934669A1 (en) 2015-06-25
AU2014368906A1 (en) 2016-07-21
MX394252B (es) 2025-03-21
JP2017502017A (ja) 2017-01-19
EP3082800A2 (en) 2016-10-26
BR112016014481A2 (pt) 2018-02-20
EP4043017A1 (en) 2022-08-17
WO2015095819A2 (en) 2015-06-25
JP6678585B2 (ja) 2020-04-22
EP3082800A4 (en) 2017-07-05
AU2014368906B2 (en) 2020-04-30
MX2021008610A (es) 2022-07-27
MX384721B (es) 2025-03-14
CN106211755A (zh) 2016-12-07
ES2909910T3 (es) 2022-05-10
CN106211755B (zh) 2021-06-22

Similar Documents

Publication Publication Date Title
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2018008694A (es) Metodos y composiciones para tratar la hiperhidrosis.
MX2017011018A (es) Inhibicion de la actividad de olig2.
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
MX2017015532A (es) Terapia de combinacion pac-1.
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2019002259A (es) Inhibicion de la actividad de la olig2.
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
MX2015012716A (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.